Don't blink, otherwise you could miss another innovative cancer drug hitting pharmacy shelves.
This experimental anti-cancer drug has jaw-dropping commercial potential.
Investment decisiones should be based on future potential, not past dividend growth.
Gilead's pan-genotypic hepatitis C virus combo, Epclusa, could significantly boost the company's sales by filling some important niches.
The approval of Epclusa could shake up how doctors treat hepatitis C patients with tough-to-treat genotypes of the disease.
The PARP inhibitor space is hot.
Drug companies tend to offer investors some of the highest dividend yields from the healthcare sector. But only two of seven pharmaceutical stocks currently yielding more than 3% are worth buying.
It's a showdown between the healthcare conglomerate and the diabetes pioneer.
A collection of underperforming stocks held by Soros Fund Management that could be set to bounce strongly.
Here's a look at the reasons why shares of Cempra jumped last month.